Related Experiment Video

Updated: May 16, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.2K

A Bivalent Molecular Glue Linking Lysine Acetyltransferases to Oncogene-induced Cell Death

Meredith N Nix1,2, Sai Gourisankar1, Roman C Sarott1

  • 1Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.

Biorxiv : the Preprint Server for Biology
|April 1, 2025
PubMed

Insights

Researchers developed novel chemical inducers of proximity (KAT-TCIPs) to target diffuse large B cell lymphoma. These compounds activate cell death genes by redirecting epigenetic modifiers, offering a new precision epigenetic therapy approach.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Robust cancer cell death is crucial for preventing relapse in therapies like immunotherapy.
  • Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, necessitating targeted treatment strategies.

Purpose of the Study:

  • To provide structural and molecular insights into a novel approach for specific cell killing in DLBCL using chemical induced proximity.
  • To develop and characterize KAT-TCIPs (lysine acetyltransferase transcriptional/epigenetic chemical inducers of proximity) for targeted cancer therapy.

Main Methods:

  • Development of KAT-TCIPs to redirect p300 and CBP.
  • Activation of programmed cell death genes repressed by the oncogenic driver BCL6.
  • Structural analysis via crystal structure of the p300-BCL6 complex.

Main Results:

  • KAT-TCIPs reprogram the epigenome to initiate apoptosis and repress c-MYC upon acute treatment.
  • The crystal structure elucidated how specific protein interactions can be exploited for potent and selective therapeutic effects.
  • Demonstrated co-option of oncogenic driver function to activate cell death.

Conclusions:

  • This study provides the foundation for precision epigenetic therapies targeting DLBCL.
  • The developed KAT-TCIPs offer a novel strategy for inducing robust cancer cell death by manipulating epigenetic regulators.
  • Exploiting oncogenic drivers for therapeutic benefit represents a promising avenue in cancer treatment.
Keywords:
induced proximitylymphomalysine acetyltransferasestranscription

More Related Videos

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions10:26

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions

Published on: December 20, 2017

9.4K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K